EA202190547A1 - Способы снижения потребности в реваскуляризации периферических артерий у субъекта, получающего лечение статинами - Google Patents
Способы снижения потребности в реваскуляризации периферических артерий у субъекта, получающего лечение статинамиInfo
- Publication number
- EA202190547A1 EA202190547A1 EA202190547A EA202190547A EA202190547A1 EA 202190547 A1 EA202190547 A1 EA 202190547A1 EA 202190547 A EA202190547 A EA 202190547A EA 202190547 A EA202190547 A EA 202190547A EA 202190547 A1 EA202190547 A1 EA 202190547A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- need
- reducing
- methods
- peripheral artery
- subject receiving
- Prior art date
Links
- 210000001367 artery Anatomy 0.000 title abstract 3
- 230000002093 peripheral effect Effects 0.000 title abstract 3
- 230000000250 revascularization Effects 0.000 title abstract 3
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 title 1
- 229920000064 Ethyl eicosapentaenoic acid Polymers 0.000 abstract 1
- SSQPWTVBQMWLSZ-AAQCHOMXSA-N ethyl (5Z,8Z,11Z,14Z,17Z)-icosapentaenoate Chemical compound CCOC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC SSQPWTVBQMWLSZ-AAQCHOMXSA-N 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
- A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862719404P | 2018-08-17 | 2018-08-17 | |
| PCT/US2019/046710 WO2020037153A1 (en) | 2018-08-17 | 2019-08-15 | Methods of reducing the need for peripheral arterial revascularization in a statin-treated subject |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA202190547A1 true EA202190547A1 (ru) | 2021-04-27 |
Family
ID=69524891
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA202190547A EA202190547A1 (ru) | 2018-08-17 | 2019-08-15 | Способы снижения потребности в реваскуляризации периферических артерий у субъекта, получающего лечение статинами |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US20220362200A1 (enExample) |
| EP (1) | EP3836914A4 (enExample) |
| JP (1) | JP2021534185A (enExample) |
| KR (1) | KR20210047312A (enExample) |
| CN (1) | CN112912071A (enExample) |
| AU (2) | AU2019321568B2 (enExample) |
| BR (1) | BR112021002884A2 (enExample) |
| CL (3) | CL2021000400A1 (enExample) |
| EA (1) | EA202190547A1 (enExample) |
| IL (1) | IL280643A (enExample) |
| MA (1) | MA52680A1 (enExample) |
| MX (1) | MX2021001906A (enExample) |
| NI (1) | NI202100009A (enExample) |
| PH (1) | PH12021550328A1 (enExample) |
| SG (1) | SG11202101562UA (enExample) |
| TN (1) | TN2021000028A1 (enExample) |
| WO (1) | WO2020037153A1 (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG175390A1 (en) | 2009-04-29 | 2011-12-29 | Amarin Corp Plc | Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same |
| PT3278665T (pt) | 2009-04-29 | 2020-11-19 | Amarin Pharmaceuticals Ie Ltd | Composição farmacêutica estável e métodos de utilização das mesmas |
| CN106074486A (zh) | 2009-06-15 | 2016-11-09 | 阿马里纳药物爱尔兰有限公司 | 在相伴他汀类疗法的对象中降低甘油三酯、没有增加ldl‑c水平的组合物和方法 |
| US20110071176A1 (en) | 2009-09-23 | 2011-03-24 | Amarin Pharma, Inc. | Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same |
| US11712429B2 (en) | 2010-11-29 | 2023-08-01 | Amarin Pharmaceuticals Ireland Limited | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
| NZ778131A (en) | 2010-11-29 | 2023-03-31 | Amarin Pharmaceuticals Ie Ltd | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
| US11291643B2 (en) | 2011-11-07 | 2022-04-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
| ES2891473T3 (es) | 2012-01-06 | 2022-01-28 | Amarin Pharmaceuticals Ie Ltd | Composiciones y métodos para reducir los niveles de alta sensibilidad (hs-CRP) en un sujeto |
| EP4338805B1 (en) | 2012-06-29 | 2025-06-04 | Amarin Pharmaceuticals Ireland Limited | Eicosapentaenoic acid ethyl ester for use in reducing the risk of non-fatal myocardial infarction in a subject on statin therapy |
| WO2014074552A2 (en) | 2012-11-06 | 2014-05-15 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy |
| US20140187633A1 (en) | 2012-12-31 | 2014-07-03 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis |
| US9452151B2 (en) | 2013-02-06 | 2016-09-27 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing apolipoprotein C-III |
| US9624492B2 (en) | 2013-02-13 | 2017-04-18 | Amarin Pharmaceuticals Ireland Limited | Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof |
| US20140271841A1 (en) | 2013-03-15 | 2014-09-18 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin |
| US10966968B2 (en) | 2013-06-06 | 2021-04-06 | Amarin Pharmaceuticals Ireland Limited | Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof |
| US20150065572A1 (en) | 2013-09-04 | 2015-03-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing prostate cancer |
| US9585859B2 (en) | 2013-10-10 | 2017-03-07 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy |
| US10561631B2 (en) | 2014-06-11 | 2020-02-18 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing RLP-C |
| WO2015195662A1 (en) | 2014-06-16 | 2015-12-23 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids |
| WO2018213663A1 (en) | 2017-05-19 | 2018-11-22 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject having reduced kidney function |
| US11058661B2 (en) | 2018-03-02 | 2021-07-13 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L |
| US11645899B2 (en) | 2018-09-14 | 2023-05-09 | Avive Solutions, Inc. | Responder network |
| US12430998B2 (en) | 2018-09-14 | 2025-09-30 | Avive Solutions, Inc. | Device based responder network activation and virtual assistant integration |
| US11640755B2 (en) | 2018-09-14 | 2023-05-02 | Avive Solutions, Inc. | Real time defibrillator incident data |
| KR20210110890A (ko) | 2018-09-24 | 2021-09-09 | 애머린 파마슈티칼스 아일랜드 리미티드 | 대상체에서 심혈관 사건의 위험도를 감소시키는 방법 |
| US12427134B2 (en) | 2019-11-12 | 2025-09-30 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of cardiovascular events in a subject with atrial fibrillation and/or atrial flutter |
| WO2021102246A1 (en) * | 2019-11-21 | 2021-05-27 | Avive Solutions, Inc. | Device based responder network activation and virtual assistant integration |
| AU2022263358A1 (en) | 2021-04-21 | 2023-11-30 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of heart failure |
| CA3217098A1 (en) * | 2021-04-29 | 2022-11-03 | Richard Louis Dunbar | Compositions comprising epa and methods of using the same for treating and/or preventing endothelial dysfunction in a subject |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090239927A1 (en) * | 2004-12-06 | 2009-09-24 | George Bobotas | Statin and Omega-3 Fatty Acids For Lipid Therapy |
| WO2008011178A2 (en) * | 2006-07-21 | 2008-01-24 | Reliant Pharmaceuticals, Inc. | Compositions comprising omega-3 fatty acids, and their use in treating peripheral artery disease and intermittent claudication |
| EP4338805B1 (en) * | 2012-06-29 | 2025-06-04 | Amarin Pharmaceuticals Ireland Limited | Eicosapentaenoic acid ethyl ester for use in reducing the risk of non-fatal myocardial infarction in a subject on statin therapy |
| US20140322314A1 (en) * | 2013-04-29 | 2014-10-30 | Matinas Biopharma, Inc. | Omega-3 Fatty Acid Formulations for Use as Pharmaceutical Treatment |
| EA039310B1 (ru) * | 2015-02-26 | 2022-01-12 | Санофи Байотекнолоджи | Способы снижения сердечно-сосудистого риска |
| US10406130B2 (en) * | 2016-03-15 | 2019-09-10 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids |
| SI3275438T1 (sl) * | 2016-07-29 | 2021-05-31 | Kowa Company, Ltd. | Metode preprečevanja kardiovaskularnih dogodkov pri dislipidemični populaciji z rezidualnim tveganjem |
-
2019
- 2019-08-15 SG SG11202101562UA patent/SG11202101562UA/en unknown
- 2019-08-15 JP JP2021507918A patent/JP2021534185A/ja active Pending
- 2019-08-15 US US17/275,576 patent/US20220362200A1/en not_active Abandoned
- 2019-08-15 MX MX2021001906A patent/MX2021001906A/es unknown
- 2019-08-15 MA MA52680A patent/MA52680A1/fr unknown
- 2019-08-15 EA EA202190547A patent/EA202190547A1/ru unknown
- 2019-08-15 CN CN201980069084.5A patent/CN112912071A/zh active Pending
- 2019-08-15 AU AU2019321568A patent/AU2019321568B2/en active Active
- 2019-08-15 WO PCT/US2019/046710 patent/WO2020037153A1/en not_active Ceased
- 2019-08-15 TN TNP/2021/000028A patent/TN2021000028A1/en unknown
- 2019-08-15 KR KR1020217007524A patent/KR20210047312A/ko not_active Ceased
- 2019-08-15 EP EP19849946.9A patent/EP3836914A4/en active Pending
- 2019-08-15 BR BR112021002884-6A patent/BR112021002884A2/pt not_active Application Discontinuation
-
2021
- 2021-02-04 IL IL280643A patent/IL280643A/en unknown
- 2021-02-16 PH PH12021550328A patent/PH12021550328A1/en unknown
- 2021-02-16 CL CL2021000400A patent/CL2021000400A1/es unknown
- 2021-02-16 NI NI202100009A patent/NI202100009A/es unknown
- 2021-12-03 CL CL2021003221A patent/CL2021003221A1/es unknown
- 2021-12-03 CL CL2021003222A patent/CL2021003222A1/es unknown
-
2024
- 2024-08-21 US US18/810,687 patent/US20250186386A1/en active Pending
-
2025
- 2025-04-22 AU AU2025202801A patent/AU2025202801A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MA52680A1 (fr) | 2021-11-30 |
| SG11202101562UA (en) | 2021-03-30 |
| PH12021550328A1 (en) | 2021-10-04 |
| AU2025202801A9 (en) | 2026-03-05 |
| CA3109774A1 (en) | 2020-02-20 |
| CL2021003222A1 (es) | 2022-07-22 |
| AU2019321568A1 (en) | 2021-03-11 |
| JP2021534185A (ja) | 2021-12-09 |
| MX2021001906A (es) | 2021-04-28 |
| CN112912071A (zh) | 2021-06-04 |
| AU2025202801A1 (en) | 2025-05-08 |
| KR20210047312A (ko) | 2021-04-29 |
| CL2021000400A1 (es) | 2021-07-02 |
| IL280643A (en) | 2021-03-25 |
| EP3836914A4 (en) | 2022-05-18 |
| WO2020037153A1 (en) | 2020-02-20 |
| US20250186386A1 (en) | 2025-06-12 |
| CL2021003221A1 (es) | 2022-07-22 |
| NI202100009A (es) | 2021-06-22 |
| US20220362200A1 (en) | 2022-11-17 |
| AU2019321568B2 (en) | 2025-01-30 |
| TN2021000028A1 (en) | 2022-10-03 |
| EP3836914A1 (en) | 2021-06-23 |
| BR112021002884A2 (pt) | 2021-05-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA202190547A1 (ru) | Способы снижения потребности в реваскуляризации периферических артерий у субъекта, получающего лечение статинами | |
| CL2023000767A1 (es) | Métodos para reducir el riesgo de eventos cardiovasculares en un sujeto. | |
| MX2022015272A (es) | Inhibidores de la proteina kras g12c y usos de estos. | |
| EA202090955A1 (ru) | Способы применения ингибиторов ehmt2 в лечении или предупреждении нарушений со стороны крови | |
| SG11201810270SA (en) | Multispecific antigen-binding molecules having blood coagulation factor viii (fviii) cofactor function-substituting activity and pharmaceutical formulations containing such a molecule as an active ing | |
| EA201500069A1 (ru) | Способы уменьшения риска развития сердечно-сосудистого события у субъекта, получающего терапию статином | |
| MX2021009806A (es) | Ésteres de ácidos grasos de cadena media de beta-hidroxibutirato y butanodiol y composiciones y métodos para usar los mismos. | |
| MX2018010983A (es) | Derivado de 3-desoxi y composiciones farmaceuticas del mismo. | |
| EA201890859A1 (ru) | Предотвращение, лечение и обращение развития заболевания с применением терапевтически эффективных количеств активированных жирных кислот | |
| EA201990550A1 (ru) | Офтальмологический препарат, включающий азоловое соединение | |
| EA202191378A1 (ru) | Активные сложноэфирные производные тестостерона, их композиции и применения | |
| EA202091885A1 (ru) | Формы сокристаллов аналога новобиоцина и пролина | |
| EA202190014A1 (ru) | Композиция, содержащая глицирризин, и ее косметическое средство и фармацевтические применения | |
| EA201992149A1 (ru) | Комбинация активных ингредиентов, содержащие ее композиции и их применение в лечении саркопении | |
| EA202190859A8 (ru) | Способы снижения риска сердечно-сосудистых событий у субъекта | |
| PH12021500016A1 (en) | Methods of reducing the risk of cardiovascular events in a subject | |
| ZA202310640B (en) | Methods of reducing the risk of heart failure | |
| EA202090333A1 (ru) | Фармацевтические комбинации, содержащие антитело к bst1 и аналог цитидина | |
| MA60150A1 (fr) | Procédés de réduction du risque d'événements cardiovasculaires chez un sujet | |
| EA202191103A1 (ru) | Терапевтические соединения | |
| EA202191612A1 (ru) | Введение сулькардина для лечения острой фибрилляции предсердий | |
| JOP20220097A1 (ar) | كريزانليزوماب يحتوي على صياغات اجسام مضادة | |
| EA201991502A1 (ru) | Композиции на основе аминокислот и способы лечения заболеваний печени | |
| EA202193050A1 (ru) | Фармацевтическая комбинация, включающая тразодон, для лечения нейропатической боли | |
| BR112019002799A8 (pt) | Composto, composição farmacêutica, método para tratar um indivíduo tendo uma doença neurodegenerativa, método para tratar um indivíduo tendo a doença de alzheimer e método para tratar um indivíduo tendo uma doença ou condição |